Fadrozole hydrochloride hemihydrate is an orally active, potent, selective and nonsteroidalaromataseinhibitor, with anIC₅₀of 6.4 nM. Fadrozole hydrochloride hemihydrate inhibits the production of estrogen and progesterone, withIC₅₀values of 0.03 and 120 μM. Fadrozole hydrochloride hemihydrate shows prevention of spontaneous tumours. Fadrozole hydrochloride hemihydrate can be used for the research of estrogen-dependent disease andcancer^[1][2][3].

IC50: 6.4 nM (aromatase)^[1]

Synthesis of other cytochrome P-450 dependent steroids can be suppressed to various degrees with higher doses of Fadrozole hydrochloride hemihydrate^[1].

Fadrozole hydrochloride hemihydrate is able to inhibit the aromatase-mediated uterine hypertrophy in immature female rats with an ED₅₀of 0.03 mg/kg when given orally^[1].
Fadrozole hydrochloride hemihydrate prevents the development of both benign and malignant spontaneus mammary neoplasns in female Sprague-Dawley rats. It also slows the spontaneous development of ptuitary pars distalis adenomas in female rats, and reduces the incidence of spontaneous hepatocellular tumours in male and female rats^[2].
Administration of Fadrozole hydrochloride hemihydrate in male and female mice accompanies with a 70% reduction in parasite burden. This protective effect is associated in male mice with a recovery of the specific cellular immune response^[3].

268.74

C₁₄H₁₃N₃.ClH.1/2H₂O

176702-70-8

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.